Apimeds Pharmaceuticals US (APUS) Shares Outstanding (2023 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Shares Outstanding (Entity) came in at $1.3 million in Q4 2025, up 59.11% YoY from $790385.0 in Q4 2024, and little changed on a QoQ basis from $1.3 million in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Shares Outstanding (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 3 years of Shares Outstanding (Entity) data on file, last reported at $1.3 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 59.11% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (up 59.11% YoY) and the FY2025 annual result came in at $1.3 million, up 59.11% from the prior year.
- Shares Outstanding (Entity) held at $1.3 million in Q4 2025, from $1.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $1.3 million in Q3 2025 to a low of $459826.0 in Q4 2023.
- A 3-year average of $884873.3 and a median of $790385.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) jumped 71.89% — and 2025, when it changed 0.0%.
- Tracing APUS's Shares Outstanding (Entity) over 3 years: stood at $459826.0 in 2023, then jumped by 71.89% to $790385.0 in 2024, then soared by 59.11% to $1.3 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $1.3 million (Q4 2025), $1.3 million (Q3 2025), and $1.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | 8.89 Bn |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | 1.08 Bn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 499.50 Mn |
| 10 | Apimeds Pharmaceuticals US | 4.37 Mn | 4.37 Mn | - | 1.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 1.26 Mn |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 790,385.00 |
| Dec 31, 2024 | 790,385.00 |
| Sep 30, 2024 | 790,385.00 |
| Jun 30, 2024 | 790,385.00 |
| Mar 31, 2024 | 790,385.00 |
| Dec 31, 2023 | 459,826.00 |